Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?

@article{Cao2011AntiangiogenicCT,
  title={Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?},
  author={Yihai Cao},
  journal={The International journal of developmental biology},
  year={2011},
  volume={55 4-5},
  pages={557-62}
}
The tumor vasculature is an increasingly attractive target for development of anticancer drugs. The fundamental principle for antiangiogenic cancer therapy is based on the inhibitory effect of chemical compounds, proteins or nucleotides on tumor angiogenesis. Indeed, in almost all preclinical tumor models, antiangiogenic monotherapy with different agents shows potent effects on suppression of tumor growth. However, antiangiogenic monotherapy has barely produced any clinical benefits in cancer… CONTINUE READING